Compare Airbnb, Inc. (ABNB) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Airbnb, Inc. vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Airbnb, Inc. trades at $184.64 (market cap $110.60B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B). The key difference: Airbnb, Inc. is far larger — about 11.8× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap. Which is the better fit depends on your goals.
| ABNB | BIO | |
|---|---|---|
Market Cap | $110.60B | $9.39B |
Sector | Consumer Cyclical | Health |
52-Week High | $184.98 | $356.25 |
52-Week Low | $111.54 | $241.71 |
Enterprise Value | $101.02B | $9.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Airbnb (ABNB) is trading at $178.07, up 17.43% with strong momentum after Q2 2026 earnings beat expectations. The stock is approaching four-year highs with bullish technical indicators and positive analyst sentiment. Revenue growth accelerated to $12.24B in 2025 with robust 82.9% gross margins, though recent quarters showed mixed earnings performance with two misses and one beat.
Outlook remains positive with AI-driven growth initiatives and expanding service offerings, but elevated valuation multiples (P/E 40.66) and competitive pressures present risks. Analyst consensus leans bullish with 46.7% buy ratings and $173.26 price target, though current price exceeds consensus target by 2.8%.
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Airbnb, Inc.
Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.
Read more on ABNB →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
